Key populations brief
Accessed November 2017
Time for recognition of lay counsellors
Accessed November 2017
This technical package represents a select group of strategies based on the best available evidence to help communities and states sharpen their focus on prevention activities with the greatest potential to prevent suicide
World's largest Science, Technology & Medicine Open Access book publisher
Chapter 7 from the book People's Movements in the 21st Century - Risks, Challenges and Benefits
Scientific advice
Prevention and control of communicable diseases in prison settings.
Blueprint for EECA countries, first edition
TB policies in 29 Countries
A survey of prevention, testing and treatment policies and practices
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 23, No. 11, November 2017
WHO working group on HIV incidence assays meeting report
10–11 December 2015
Glion, Switzerland
UNAIDS/WHO working group on global HIV/AIDS and STI surveillance
WHO/HIV/2017.03
Tackling Tuberculosis in Under-Served Populations: A Resource for TB Control Boards and their partners
Technical Update
HIV Treatment
July 2017
Lymphatic filariasis is a vector-borne neglected tropical disease that causes damage of the lymphatic system and can lead to lymphoedema (elephantiasis) and hydrocele in infected individuals. The global baseline estimate of persons affected by lymphatic filariasis is 25 million men with hydrocele an...d over 15 million people with lymphoedema. At least 36 million persons remain with these chronic disease manifestations. The disease is endemic in 72 countries. In 2016, an estimated total population of 856 million were living in areas with ongoing transmission of the causative filarial parasites and requiring mass drug administration (MDA). Lymphatic filariasis disfigures and disables, and often leads to stigmatization and poverty. Hundreds of millions of dollars are lost annually due to reduced productivity of affected patients. WHO has ranked the disease as one of the world’s leading causes of permanent and long-term disability.
more
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more